MAIA Biotechnology, Inc. (MAIA)
NYSEAMERICAN: MAIA · Real-Time Price · USD
1.330
+0.030 (2.31%)
Sep 14, 2026, 9:55 AM EDT - Market open
MAIA Biotechnology Employees
MAIA Biotechnology had 13 employees as of December 31, 2025. The number of employees did not change compared to the previous year.
Employees
13
Change (1Y)
n/a
Growth (1Y)
n/a
Revenue / Employee
n/a
Profits / Employee
-$2,065,015
Market Cap
80.90M
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 13 | 0 | - |
| Dec 31, 2024 | 13 | 0 | - |
| Dec 31, 2023 | 13 | -5 | -27.78% |
| Dec 31, 2022 | 18 | 9 | 100.00% |
| Dec 31, 2021 | 9 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| Pelthos Therapeutics | 92 |
| Fortress Biotech | 78 |
| iBio, Inc. | 23 |
| Gain Therapeutics | 21 |
| RenovoRx | 17 |
| Yarrow Bioscience | 7 |
| Aldeyra Therapeutics | 6 |
| OS Therapies | 5 |
MAIA News
- 4 days ago - MAIA Biotechnology Delivers Oral and Poster Presentations Showcasing Next-Generation Telomere-Targeting Cancer Therapies at IRT 2026 - GlobeNewsWire
- 23 days ago - MAIA Biotechnology files $150M mixed securities shelf - TheFly
- 24 days ago - MAIA Biotechnology Registration statement: Registration filing - Filings
- 4 weeks ago - Diamond Equity Research Releases Update Note on MAIA Biotechnology, Inc. (NYSE: MAIA) - GlobeNewsWire
- 5 weeks ago - MAIA Biotechnology Quarterly report: Q2 2026 - Filings
- 2 months ago - MAIA Biotechnology reports efficacy data from Phase 2 THIO-101 Part C expansion - TheFly
- 2 months ago - MAIA Biotechnology Reports Strong Initial Efficacy Data in Third-Line Non-Small Cell Lung Cancer from Phase 2 THIO-101 Part C Expansion Trial - GlobeNewsWire
- 2 months ago - MAIA Biotechnology Completes International Enrollment in Part C of Phase 2 THIO-101 Expansion Trial in Third-Line Non-Small Cell Lung Cancer - GlobeNewsWire